目的 探討注射用烏司他丁聯(lián)合參麥注射液治療感染性休克的臨床研究。方法 選取2014年2月—2017年6月在安陽市人民醫(yī)院診治的感染性休克患者70例作為研究對象，隨機分為觀察組（35例）和對照組（35例）。對照組患者以5 mL/h的速度持續(xù)泵入?yún)Ⅺ溩⑸湟?2 h。觀察組患者在對照組基礎(chǔ)上靜脈滴注注射用烏司他丁，將20萬U溶解于100 mL生理鹽水內(nèi)，2次/d。兩組均連續(xù)治療3 d。觀察兩組患者的臨床療效，比較兩組血清C反應(yīng)蛋白（CRP）、降鈣素原（PCT）、白細胞介素-6（IL-6）水平、病死率及多器官功能障礙綜合征（MODS）發(fā)生率。結(jié)果 治療后，觀察組患者臨床治療有效率為94.29%，對照組患者的臨床治療有效率為71.43%，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組患者血清內(nèi)CRP、PCT及IL-6水平均明顯降低，同組治療前后比較差異有統(tǒng)計學(xué)意義（P<0.05）；且觀察組患者CRP、PCT及IL-6水平均顯著低于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。與對照組相比，觀察組患者的病死率和MODS發(fā)生率均顯著降低，差異具有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 注射用烏司他丁聯(lián)合參麥注射液治療感染性休克的臨床效果較好，可顯著降低血清炎性反應(yīng)并有效改善病死率。

Objective To investigate the clinical research of Ulinastatin for Injection combined with Shenmai Injection in treatment of septic shock. Methods Patients (70 cases) with septic shock in The People's Hospital of Anyang City from Feburary 2014 to June 2017 were randomly divided into observation group (35 cases) and control group (35 cases). Patients in the control group were continuously pumped Shenmai Injection for 12 h at the rate of 5 mL/h. Patients in the observation group were iv administered with Ulinastatin for Injection on the basis of control group, 200 000 U dissolved in 100 mL normal saline, twice daily. Patients in two groups were treated for 3 d. After treatment, the clinical efficacies were evaluated, and the serum CRP, PCT, IL-6 levels, mortality and MODS in two groups were compared. Results After treatment, the effective rate in the observation group was 94.29%, the effective rate in the control group was 71.43%, and there was difference between two groups (P<0.05). After treatment, the serum CRP, PCT and IL-6 levels in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the levels of CRP, PCT and IL-6 in the observation group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Compared with the control group, the mortality and the incidence of multiple organ disfunction syndrome in the observation group were significantly decreased, the difference was statistically significant (P<0.05). Conclusion Ulinastatin for Injection combined with Shenmai Injection has good clinical effect in treatment of septic shock, can significantly decreased the serum inflammatory response, and effectively improve mortality.